- Home
- ASPI vs SVRA Comparison
ASPI vs SVRA Comparison
Compare ASPI & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASPI
- SVRA
- Stock Information
- Founded
- ASPI 2021
- SVRA 2007
- Country
- ASPI United States
- SVRA United States
- Employees
- ASPI N/A
- SVRA N/A
- Industry
- ASPI Major Chemicals
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- ASPI Industrials
- SVRA Health Care
- Exchange
- ASPI Nasdaq
- SVRA Nasdaq
- Market Cap
- ASPI 470.6M
- SVRA 528.3M
- IPO Year
- ASPI 2022
- SVRA N/A
- Fundamental
- Price
- ASPI $7.57
- SVRA $2.06
- Analyst Decision
- ASPI Strong Buy
- SVRA Buy
- Analyst Count
- ASPI 2
- SVRA 7
- Target Price
- ASPI $7.75
- SVRA $7.57
- AVG Volume (30 Days)
- ASPI 4.6M
- SVRA 2.5M
- Earning Date
- ASPI 08-18-2025
- SVRA 08-11-2025
- Dividend Yield
- ASPI N/A
- SVRA N/A
- EPS Growth
- ASPI N/A
- SVRA N/A
- EPS
- ASPI N/A
- SVRA N/A
- Revenue
- ASPI $4,405,477.00
- SVRA N/A
- Revenue This Year
- ASPI $512.64
- SVRA N/A
- Revenue Next Year
- ASPI $181.15
- SVRA N/A
- P/E Ratio
- ASPI N/A
- SVRA N/A
- Revenue Growth
- ASPI 245.97
- SVRA N/A
- 52 Week Low
- ASPI $1.86
- SVRA $1.89
- 52 Week High
- ASPI $10.08
- SVRA $5.11
- Technical
- Relative Strength Index (RSI)
- ASPI 48.06
- SVRA 34.43
- Support Level
- ASPI $7.55
- SVRA $2.13
- Resistance Level
- ASPI $8.12
- SVRA $2.49
- Average True Range (ATR)
- ASPI 0.75
- SVRA 0.15
- MACD
- ASPI -0.21
- SVRA -0.01
- Stochastic Oscillator
- ASPI 20.32
- SVRA 8.41
About ASPI ASP Isotopes Inc.
ASP Isotopes Inc is a pre-commercial stage advanced materials company dedicated to the development of technology and processes that, if successful, will allow for the production of isotopes that may be used in several industries. The company utilizes technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.